CELZ · Creative Medical Technology Holdings Inc.
AI read · Neutral
The AI's read
CELZ announced a USPTO Notice of Allowance for a diabetes-related exosome patent and shares exploded roughly 100% intraday. The market is clearly assigning value to strengthened IP around the MyoCelz platform. The move looks largely priced in. Shares are up ~101% and RSI is 71.88, so momentum is stretched and expectations are high. Our take is neutral. The patent is real progress, but upside appears limited after the run and whipsaw risk is high in the current consolidation regime.